Oh, Richard

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial

Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 142

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 130

Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide

Januzzi, J. L., Xu, J., Li, J., Shaw, W., Oh, R., Pfeifer, M., Butler, J., Sattar, N., Mahaffey, K. W., Neal, B., et al. (2020) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 97

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials

Zhou, Z., Lindley, R. I., Rådholm, K., Jenkins, B., Watson, J., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Shaw, W., et al. (2019) · Stroke

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 72

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021) · Clinical Kidney Journal

Diabetes Treatment and ManagementPotassium and Related Disorders

Cited by 31